Curadel Pharma has initiated the Phase 3 portion of its pivotal study for ZW800-1 (nizaracianine triflutate), following successful Phase 2 results that met primary endpoints with a favorable safety profile.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.